US pharma giant Merck & Co (NYSE: MRK) posted revenue of $10.43 billion for the fourth quarter of 2017, a rise of 3% compared with the like 2016 period, but missed analysts’ consensus expectations of $10.5 billion.
Its pharmaceuticals business, which accounts for the vast majority, grew 4% to $9.3 billion in the quarter, with its Keytruda (pembrolizumab) generating sales of almost $1.3 billion, a year-on-year rise of 169%.
Merck recorded a net loss of $872 million, or $0.32 share, compared with a net loss of $594 million, or $0.22 per share, in the year-earlier quarter. The company’s shares were down 2.17% at $58.56 by close of trading on Friday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze